CT-388 vs VK2735: Roche's Dual Agonist Entry vs Viking's Lead Asset
By FormBlends Medical Team · Last updated: April 25, 2026
VK2735 is ahead. CT-388 is still more of a watchlist asset than a category-defining one. That can change, but today this is mainly a comparison between a late-stage contender and a promising chaser.
How to Use This Comparison
Use this comparison as a decision aid, not a prescription shortcut. VK2735 is Phase 3, while CT-388 is Phase 2. CT-388 is usually a better fit for readers tracking roche's chance to become more relevant in obesity from a mid-stage position, while VK2735 is usually a better fit for readers who care more about which mid-cap obesity story is already closest to the real league table. Cost also matters: CT-388 is listed at Trial-stage asset; pricing unknown, while VK2735 is listed at Trial-stage asset; launch pricing unknown. Because this comparison is framed as an either-or decision, the safety question is which option fits your health history, side-effect tolerance, and access path.
PubMed evidence trail
Research sources used to frame this page
For CT-388 vs VK2735: Roche's Dual Agonist Entry vs Viking's Lead Asset, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
CT-388 vs VK2735: Roche's Dual Agonist Entry vs Viking's Lead Asset should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Head-to-Head Comparison
CT-388
Pipeline Compound
Strengths
- Backed by Roche, which gives it serious scale if it works
- GLP-1/GIP profile keeps it in a proven mechanism class
- Still early enough to surprise if development accelerates
Weaknesses
- Phase 2 status leaves more room for failure
- Still behind VK2735 in visibility and maturity
Best For
Readers tracking Roche's chance to become more relevant in obesity from a mid-stage position.
Typical Cost
Trial-stage asset; pricing unknown
VK2735
Pipeline Compound
Strengths
- Phase 3 and already treated as one of the most important independent obesity assets
- Cleaner current momentum and greater investor familiarity
- More advanced path toward real-world commercialization
Weaknesses
- Competition is intense in the same mechanism lane
- Execution risk rises as the asset gets closer to the market
Best For
Readers who care more about which mid-cap obesity story is already closest to the real league table.
Typical Cost
Trial-stage asset; launch pricing unknown
Key Differences
- 1VK2735 is Phase 3, while CT-388 is Phase 2
- 2Both are GLP-1/GIP programs, so the major difference is maturity and sponsor context
- 3Roche brings scale to CT-388, but Viking currently has the clearer obesity-market momentum
- 4VK2735 is judged on near-term conversion; CT-388 is judged on whether it can catch up
Frequently Asked Questions
What is the difference between CT-388 and VK2735?
VK2735 is Phase 3, while CT-388 is Phase 2. Both are GLP-1/GIP programs, so the major difference is maturity and sponsor context.
Which is more effective, CT-388 or VK2735?
VK2735 is ahead. CT-388 is still more of a watchlist asset than a category-defining one. That can change, but today this is mainly a comparison between a late-stage contender and a promising chaser.
How much does CT-388 cost compared to VK2735?
CT-388 typically costs Trial-stage asset; pricing unknown, while VK2735 typically costs Trial-stage asset; launch pricing unknown.
Who should choose CT-388 over VK2735?
CT-388 is best for: Readers tracking Roche's chance to become more relevant in obesity from a mid-stage position.. VK2735 is best for: Readers who care more about which mid-cap obesity story is already closest to the real league table..
Ready to get started?
Connect with a licensed provider who can help you decide between CT-388 and VK2735 based on your goals, health history, and budget.